<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168308</url>
  </required_header>
  <id_info>
    <org_study_id>STU 032017-030</org_study_id>
    <nct_id>NCT03168308</nct_id>
  </id_info>
  <brief_title>Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients</brief_title>
  <official_title>Sugammadex Versus Neostigmine for Reversal of Rocuronium-induced Neuromuscular Blockade: A Study of Thoracic Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, double blinded study is intended to enroll a total of 92
      patients undergoing thoracic surgery with general endotracheal anesthesia at Parkland
      Hospital. Patients will be randomized to receive either neostigmine or sugammadex for
      reversal of neuromuscular blockade. Merck, Inc. will supply the sugammadex through an
      agreement with Parkland Investigational Drug Services. Neostigmine is readily available for
      anesthesiologists to use and is the current standard of care for reversal of neuromuscular
      blockade. A standardized anesthetic protocol that is usual and customary for the type of
      operation the patient is having will be provided to the anesthesia teams of enrolled
      subjects. The remainder of the anesthetic care of the subject will not deviate from the
      standard of care. The surgeon, anesthesia team, postoperative recovery nurse, and research
      assistant will be blinded as to which reversal drug the patient receives. The only individual
      that will know to which drug the patient has been randomized will be the pharmacist who draws
      up the medication(s). A blinded research assistant will record postoperative outcomes and the
      patient will be followed 90 minutes postoperatively for any adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening and Informed Consent:

      A member of the research team will use a screening form to look for surgical patients that
      meet all of the inclusion and exclusion criteria. He/she will approach potential subjects
      during pre-anesthesia evaluation clinic (PAEC). Patients who are unable to be consented in
      PAEC will be approached in the preoperative area and the study will be explained in detail in
      a private room. Patients will be informed that they will receive no compensation for
      participating in the study and there will be no adverse consequences if they choose not to
      participate. If the subjects agree to participate, informed written consent will be obtained
      prior to any study procedures and this document will be sent to
      pmhresearchparticipants@phhs.org, for inclusion in the patient's medical record, per Parkland
      regulations. The study duration is from the start of anesthesia to 90 minutes
      postoperatively.

      Anesthesia Protocol:

      The anesthesia team that will be caring for the subject during surgery will be given the
      protocol for the study, which standardizes the general anesthetic technique. All patients
      will receive 0.6 mg/kg of rocuronium for neuromuscular paralysis during induction. Additional
      rocuronium will be given in 0.15 mg/kg increments to keep the patient at a neuromuscular
      depth of 1 twitch throughout the surgery. All patients will have the depth of neuromuscular
      block monitored at the non-dominant ulnar nerve at 60 mA with a TOF Watch accelerometer
      device, which provides real time feedback of the strength of contraction and graphically
      displays the relevant ratios.

      Maintenance of anesthesia will be with sevoflurane in 70% oxygen, titrated to keep the
      bispectral index (BIS) between 40-60. All patients will have a forced air warming device
      (e.g., Bair Hugger, 3M, Maplewood, MN) used to maintain normothermia throughout the surgery.
      Subjects will be randomized to receive blinded study drug: either neostigmine or sugammadex
      for reversal of neuromuscular blockade, which will be administered intravenously at the
      beginning of skin closure. The anesthesia team will be blinded. The blinded study drug
      (reversal agent(s)) will be prepared into a 10 mL syringe by a pharmacist in Investigational
      Drug Service (IDS) Pharmacy and labeled in a blinded fashion as &quot;sugammadex or
      neostigmine/glycopyrrolate.&quot; Any volume of blinded study drug (reversal agent(s)) that is
      less than 10 mL will be supplemented with 0.9% normal saline solution, preservation-free so
      that all syringes contain a volume of 10 mL and appear identical in order to preserve
      blinding. Any patient with clinical signs of inadequate reversal or failure of recovery of
      neuromuscular function [TOFR &lt; 0.2] at 20 min after reversal will receive a rescue dose of
      sugammadex. The remaining aspects of the anesthetic will be standardized and not differ from
      the standard of care and will be similar for all patients.

      Randomization &amp; Dosing:

      Patients will be randomized to one of two groups for reversal of neuromuscular paralysis:

        1. Group 1- neostigmine (NEO group)

             1. Neostigmine 50 mcg/kg, maximum 5 mg

             2. Glycopyrrolate, 8 mcg/kg, maximum 1 mg

        2. Group 2- sugammadex (SUG group). a. Sugammadex 2 mg/kg

      The research coordinator will make randomization envelopes by using a random number
      generator. These envelopes will be provided to IDS Pharmacy before any subjects are screened
      and later only as needed to replenish supply. The words 'neostigmine/glycopyrrolate' or
      'sugammadex' will be printed on a piece of paper and placed in an opaque manila envelope that
      bears a unique subject number (#). Upon receiving the physician order for the subject, the
      IDS Pharmacist will randomize the subject to a treatment group by opening the randomization
      envelope bearing the subject # corresponding to the subject # written on the physician order.

      The Investigator or Co-Investigator will write the patient's total body weight (TBW) on the
      physician order so that the pharmacist can perform necessary dose calculations and draw up
      the appropriate intravenous dose of the blinded study drug (reversal agent(s)): sugammadex OR
      neostigmine/glycopyrrolate. After the blinded study drug syringe is prepared, a pharmacist or
      pharmacy technician will deliver the syringe to the operating room to the anesthesia
      provider, who will sign for receipt of the study drug syringe.

      Blinding/Un-blinding:

      The patient, all medical providers (surgeons, anesthesia faculty, anesthesia residents,
      certified registered nurse anesthetists, nurses), and the postoperative evaluator will be
      blinded as to what reversal agent (sugammadex versus neostigmine/glycopyrrolate) the patient
      receives. A member of the research team that is not involved in the direct care or assessment
      of the patient will provide the randomization envelopes to IDS Pharmacy. IDS Pharmacy staff
      will be the only un-blinded personnel.

      In emergency scenarios where un-blinding becomes necessary (e.g., anaphylaxis), the Principal
      Investigator or Co-Investigators may call the IDS Pharmacy to ascertain which specific
      medication(s) was dispensed. A detailed log of patient enrollments, randomization assignments
      and drug accountability will be kept in Investigational Drug Service (IDS) Pharmacy, which
      has controlled security access.

      Calculation of Key Times:

      The time that the reversal agent (sugammadex versus neostigmine) is given will be marked as
      'Reversal Time', and times to last stitch, extubation, and out of OR will be ascertained from
      the electronic medical record (EMR) (i.e., Epic Systems, Verona, WI). A trained research
      assistant will assess the degree of neuromuscular function the patient has in the early
      postoperative period. Adequate reversal will be defined as a train of four ratio (TOFR) â‰¥
      0.9. Anything less than 0.9 will be defined as residual paralysis or inadequate reversal.

      Postoperative Recovery Assessment:

      A blinded, trained research assistant will observe and record all parameters during the early
      postoperative period. All episodes of hypoxia will be recorded and any use of supplemental
      oxygen will be recorded. A standard O2 weaning protocol will be used in the PACU. All vital
      signs will be extracted from the EMR. Any drugs given will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Hypoxic Episodes</measure>
    <time_frame>Through patient's stay in the early postoperative period, approximately 1-2 hours.</time_frame>
    <description>Hypoxia was defined as an episode of peripheral oxygen saturation (SpO2) &lt;94% on â‰¤2 L/min of oxygen by nasal cannula, or a SpO2 &lt;98% on â‰¥2 L/min of oxygen, or postoperative SpO2 of â‰¥5% reduction compared to preoperative values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Reversal of Neuromuscular Blockade</measure>
    <time_frame>From time of reversal to complete reversal of neuromuscular blockade (train of four ratio â‰¥0.9), approximately 1 hour</time_frame>
    <description>The time from the administration of the blinded reversal syringe until complete reversal of neuromuscular blockade (train of four ratio â‰¥0.9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Needed Rescue Sugammadex After Initial Reversal of Neuromuscular Blockade</measure>
    <time_frame>From time of reversal to 80 minutes after arrival in the post-anesthesia care unit, approximately 1-2 hours.</time_frame>
    <description>To determine if reversal with sugammadex versus neostigmine requires an additional dose of sugammadex rescue after initial reversal of neuromuscular blockade.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Neostigmine &amp; Glycopyrrolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive Sugammadex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex 2 mg/kg</description>
    <arm_group_label>Sugammadex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine w/ Glycopyrrolate</intervention_name>
    <description>Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
    <arm_group_label>Neostigmine &amp; Glycopyrrolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old

          -  Undergoing non-emergent thoracic surgery

          -  ASA physical status classification 2 to 4

          -  Willing and able to consent in English or Spanish

          -  No personal history of neuromuscular disease

        Exclusion Criteria:

          -  Age less than 18 or older than 80

          -  Patient does not speak English or Spanish

          -  Planned postoperative intubation or ICU admission

          -  Allergy to sugammadex, neostigmine, glycopyrrolate, or rocuronium

          -  Family or personal history of malignant hyperthermia

          -  Patient refusal

          -  Monitored anesthesia care (MAC) or regional anesthesia planned

          -  Pregnant or nursing women

          -  &quot;Stat&quot; (emergent) cases

          -  Estimated creatinine clearance &lt;30 mL/min

          -  Pre-existing muscle weakness of any etiology

          -  Patients on toremifene (a selective estrogen receptor modulator)

          -  Women on oral contraceptives who do not wish to use a non-hormonal method of
             contraception for 7 days following surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiffany Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Health &amp; Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>January 10, 2020</results_first_submitted>
  <results_first_submitted_qc>January 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Tiffany B Moon</investigator_full_name>
    <investigator_title>Assistant Professor, Director of Resident Research</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03168308/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neostigmine &amp; Glycopyrrolate</title>
          <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate
Neostigmine w/ Glycopyrrolate: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
        </group>
        <group group_id="P2">
          <title>Sugammadex</title>
          <description>Patients randomized to receive Sugammadex
Sugammadex: Sugammadex 2 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neostigmine &amp; Glycopyrrolate</title>
          <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate
Neostigmine w/ Glycopyrrolate: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
        </group>
        <group group_id="B2">
          <title>Sugammadex</title>
          <description>Patients randomized to receive Sugammadex
Sugammadex: Sugammadex 2 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="13.8"/>
                    <measurement group_id="B2" value="53.1" spread="14.4"/>
                    <measurement group_id="B3" value="51.1" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Hypoxic Episodes</title>
        <description>Hypoxia was defined as an episode of peripheral oxygen saturation (SpO2) &lt;94% on â‰¤2 L/min of oxygen by nasal cannula, or a SpO2 &lt;98% on â‰¥2 L/min of oxygen, or postoperative SpO2 of â‰¥5% reduction compared to preoperative values.</description>
        <time_frame>Through patient's stay in the early postoperative period, approximately 1-2 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neostigmine &amp; Glycopyrrolate</title>
            <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate
Neostigmine w/ Glycopyrrolate: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex</title>
            <description>Patients randomized to receive Sugammadex
Sugammadex: Sugammadex 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoxic Episodes</title>
          <description>Hypoxia was defined as an episode of peripheral oxygen saturation (SpO2) &lt;94% on â‰¤2 L/min of oxygen by nasal cannula, or a SpO2 &lt;98% on â‰¥2 L/min of oxygen, or postoperative SpO2 of â‰¥5% reduction compared to preoperative values.</description>
          <units>episode(s)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Reversal of Neuromuscular Blockade</title>
        <description>The time from the administration of the blinded reversal syringe until complete reversal of neuromuscular blockade (train of four ratio â‰¥0.9).</description>
        <time_frame>From time of reversal to complete reversal of neuromuscular blockade (train of four ratio â‰¥0.9), approximately 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neostigmine &amp; Glycopyrrolate</title>
            <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate
Neostigmine w/ Glycopyrrolate: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex</title>
            <description>Patients randomized to receive Sugammadex
Sugammadex: Sugammadex 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Reversal of Neuromuscular Blockade</title>
          <description>The time from the administration of the blinded reversal syringe until complete reversal of neuromuscular blockade (train of four ratio â‰¥0.9).</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="15" upper_limit="53"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Needed Rescue Sugammadex After Initial Reversal of Neuromuscular Blockade</title>
        <description>To determine if reversal with sugammadex versus neostigmine requires an additional dose of sugammadex rescue after initial reversal of neuromuscular blockade.</description>
        <time_frame>From time of reversal to 80 minutes after arrival in the post-anesthesia care unit, approximately 1-2 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neostigmine &amp; Glycopyrrolate</title>
            <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate
Neostigmine w/ Glycopyrrolate: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex</title>
            <description>Patients randomized to receive Sugammadex
Sugammadex: Sugammadex 2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Needed Rescue Sugammadex After Initial Reversal of Neuromuscular Blockade</title>
          <description>To determine if reversal with sugammadex versus neostigmine requires an additional dose of sugammadex rescue after initial reversal of neuromuscular blockade.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Monitored for 24 hours after surgery end time.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Neostigmine &amp; Glycopyrrolate</title>
          <description>Patients randomized to receive Neostigmine w/ Glycopyrrolate
Neostigmine w/ Glycopyrrolate: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg</description>
        </group>
        <group group_id="E2">
          <title>Sugammadex</title>
          <description>Patients randomized to receive Sugammadex
Sugammadex: Sugammadex 2 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Critical respiratory or circulatory events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Symptoms of residual neuromuscular blockade</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reintubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tiffany Moon, MD</name_or_title>
      <organization>University of Texas Southwestern</organization>
      <phone>4694195790</phone>
      <email>Tiffany.Moon@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

